Barclays PLC raised its stake in shares of Cogent Biosciences, Inc. (NASDAQ:COGT – Get Rating) by 5,227.2% during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 148,256 shares of the technology company's stock after purchasing an additional 145,473 shares during the period. Barclays PLC owned 0.32% of Cogent Biosciences worth $2,211,000 as of its most recent SEC filing.
Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. SG Americas Securities LLC grew its holdings in Cogent Biosciences by 43.5% during the third quarter. SG Americas Securities LLC now owns 24,467 shares of the technology company's stock valued at $365,000 after purchasing an additional 7,418 shares during the last quarter. Deerfield Management Company L.P. Series C boosted its position in shares of Cogent Biosciences by 267.1% in the second quarter. Deerfield Management Company L.P. Series C now owns 5,876,805 shares of the technology company's stock valued at $53,009,000 after acquiring an additional 4,275,805 shares during the period. Amalgamated Bank bought a new stake in shares of Cogent Biosciences in the first quarter valued at approximately $37,000. Pura Vida Investments LLC bought a new stake in shares of Cogent Biosciences in the second quarter valued at approximately $2,154,000. Finally, Tekla Capital Management LLC bought a new stake in shares of Cogent Biosciences in the second quarter valued at approximately $1,325,000.
Get Cogent Biosciences alerts:Wall Street Analysts Forecast Growth
Several equities research analysts have recently weighed in on COGT shares. Guggenheim increased their price objective on Cogent Biosciences from $22.00 to $24.00 and gave the company a "buy" rating in a research report on Tuesday, December 13th. Wedbush reduced their price objective on Cogent Biosciences to $19.00 in a research report on Wednesday, November 16th. SVB Leerink increased their price objective on Cogent Biosciences from $18.00 to $20.00 and gave the company an "outperform" rating in a research report on Thursday, January 5th. Finally, Needham & Company LLC began coverage on Cogent Biosciences in a research report on Wednesday, December 14th. They issued a "buy" rating and a $24.00 price objective for the company.
Cogent Biosciences Price Performance
Shares of COGT stock opened at $15.50 on Friday. The stock has a market cap of $710.21 million, a P/E ratio of -6.20 and a beta of 1.73. Cogent Biosciences, Inc. has a one year low of $3.79 and a one year high of $18.07. The stock has a fifty day moving average price of $12.36 and a 200 day moving average price of $13.23.Cogent Biosciences (NASDAQ:COGT – Get Rating) last issued its earnings results on Monday, November 14th. The technology company reported ($0.50) EPS for the quarter, topping the consensus estimate of ($0.51) by $0.01. Equities research analysts anticipate that Cogent Biosciences, Inc. will post -2.31 EPS for the current year.
Cogent Biosciences Profile
(Get Rating)
Cogent Biosciences, Inc is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of precision therapies for genetically defined diseases. It focuses on CGT9486, a selective tyrosine kinase inhibitor that is designed to potently inhibit the KIT D816V mutation as well as other mutations in KIT exon 17.
Featured Articles
- Get a free copy of the StockNews.com research report on Cogent Biosciences (COGT)
- Cathie Woods' Ark Innovation ETF Set To Rebound in 2023?
- Mullen Automotive Stock Gains Momentum On Positive News
- Harley-Davidson Inc. Stock, Is It Time To Buy?
- The Bottom Is In For Meta Platforms, Volatility Is Not Over
- Analyzing Alaska Air's Recent Earnings
Want to see what other hedge funds are holding COGT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Cogent Biosciences, Inc. (NASDAQ:COGT – Get Rating).
Receive News & Ratings for Cogent Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cogent Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.